Non-Small Cell Lung Cancer (NSCLC)

The panel discusses how HER3-directed therapy with patritumab deruxtecan may fit into the evolving treatment paradigm for EGFR-positive lung cancer as more data emerges.

Dr. Yu and Dr. Patel examine the safety profile of patritumab deruxtecan, including adverse event monitoring and management approaches to optimize patient outcomes.

Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA-Lung01 trial.

Developers also announced that they completed enrollment of patients with non–small cell lung cancer in the phase 2 THIO-101 trial.

The expert panel analyze results from the HERTHENA-Lung01 trial, discuss efficacy outcomes with patritumab deruxtecan in pretreated EGFR-mutant metastatic NSCLC.

Dr. Patel and Dr. Yu review the rationale for targeting HER3 as a novel approach to address acquired resistance in EGFR-mutant NSCLC.

Data from the TROPION-Lung01 and TROPION-Breast01 trials support the EU marketing authorization applications for datopotamab deruxtecan in non–small cell lung cancer and breast cancer, respectively.

The regulatory agency has cleared developers to continue patient enrollment in the phase 2 IOV-LUN-202 trial evaluating LN-145 in non–small cell lung cancer.

Data from the phase 3 PAPILLON trial support the FDA approval of amivantamab plus chemotherapy for patients with metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

The nivolumab with chemotherapy regimen missed the primary end point on the phase 3 trial of patients with EGFR-mutated non–small cell lung cancer.

Expert medical oncologists examine remaining unmet needs in managing EGFR-positive lung cancer, including overcoming resistance to initial EGFR-directed therapy. The panel discusses ongoing trials targeting these needs.

Dr. Yu and Dr. Patel provide an overview of current standards and recent advances in the treatment landscape for EGFR-mutated NSCLC, emphasizing the critical role of comprehensive genomic profiling in guiding optimal therapy selection and sequencing.

Data from the phase 1 portion of the ARROS-1 trial support the breakthrough therapy designation for NVL-520 as a treatment for those with ROS1-positive non–small cell lung cancer.

Dr. Gregory Gan presents Case 4, featuring a 71-year-old diagnosed with Stage IIIA NSCLC experiencing pneumonitis following Chemo-IO treatment, prompting a discussion with expert insight on the monitoring and management of this condition.

Dr. Gregory Gan introduces Case 2, involving a 70-year-old former smoker with Stage IIIB NSCLC and a PD-L1 level of 10%, prompting discussion with emphasis on the importance of shared decision-making with the patient and their caregivers.

Findings from 3 phase 3 trials support the marketing authorization application for tislelizumab as a treatment for patients with non–small cell lung cancer in the European Union.

Preliminary findings from a phase 1 trial support the breakthrough therapy designation for BAY 2927088 as a treatment for those with unresectable or metastatic non–small cell lung cancer harboring HER2 mutations.

The European Medicine Agency’s Committee for Medicinal Products for Human Use’s recommendation of approving pembrolizumab plus chemotherapy in resectable non–small cell lung cancer is based on results from the KEYNOTE-671 trial.

Results from the phase 3 LAURA trial found a statistically significant PFS benefit and a positive trend in OS with osimertinib following chemoradiotherapy in patients with stage III EGFR-mutated non–small cell lung cancer.

Dr. Gregory Gan introduces Case 2, featuring an 82-year-old former smoker with poorly differentiated lung adenocarcinoma and a PD-L1 level of 85%, initiating a conversation on the role of a multidisciplinary approach to treatment and consideration factors for surgical and radiotherapy interventions.

Gregory Gan, MD, presents Case 1 involving a 72-year-old former smoker with Stage-IIIA NSCLC and a PD-L1 level of 90%, initiating a discussion on the treatment and management of the case.

Findings from the phase 3 TROPION-Lung01 trial support the biologics license application for datopotamab deruxtecan as a treatment for those with advanced nonsquamous non–small cell lung cancer.

Findings from the phase 2 UNICORN trial support osimertinib as a potential treatment option for patients with metastatic non–small cell lung cancer harboring uncommon EGFR mutations.

Secondary primary lung cancer rates and cumulative incidence rates were similar in multiple subgroups of patients with stage T1aN0 non–small cell lung cancer.

Data from the phase 3 FLAURA 2 trial support the FDA approval of osimertinib plus chemotherapy for treating patients with EGFR-mutated non–small cell lung cancer.